Products - Skin infections | Topic | NICE

Showing 8 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Dupilumab for treating moderate to severe prurigo nodularis (TA955)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 March 2024
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 December 2023
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 August 2021
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 June 2016
Nemolizumab for treating prurigo nodularis [ID6451]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 May 2025
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rezafungin for untreated invasive candidiasis TS ID 10768
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for treating bullous pemphigoid [ID6479]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC